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Abstract
Background: Multiple recent studies have found aberrant expression profiles of microRNAome
in human cancers. While several target genes have been experimentally identified for some
microRNAs in various tumors, the global pattern of cellular functions and pathways affected by co-
expressed microRNAs in cancer remains elusive. The goal of this study was to develop a
computational approach to global analysis of the major biological processes and signaling pathways
that are most likely to be affected collectively by co-expressed microRNAs in cancer cells.
Results: We report results of computational analysis of five datasets of aberrantly expressed
microRNAs in five human cancers published by the authors (pancreatic cancer) and others (breast
cancer, colon cancer, lung cancer and lymphoma). Using the combinatorial target prediction
algorithm miRgate and a two-step data reduction procedure we have determined Gene Ontology
categories as well as biological functions, disease categories, toxicological categories and signaling
pathways that are: targeted by multiple microRNAs; statistically significantly enriched with target
genes; and known to be affected in specific cancers.
Conclusion: Our global analysis of predicted miRNA targets suggests that co-expressed miRNAs
collectively provide systemic compensatory response to the abnormal phenotypic changes in
cancer cells by targeting a broad range of functional categories and signaling pathways known to be
affected in a particular cancer. Such systems biology based approach provides new avenues for
biological interpretation of miRNA profiling data and generation of experimentally testable
hypotheses regarding collective regulatory functions of miRNA in cancer.
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Background
microRNAs (miRNAs) are single-stranded, non-coding
RNAs approximately 22 nucleotides in length that post-
transcriptionally regulate gene expression in a sequence
specific manner by binding with imperfect complimenta-
rity at multiple sites of 3'-UTR regions of mRNA, thereby
facilitating mRNA degradation or inhibiting translation
initiation (reviewed in [1,2]). First discovered in C. ele-
gans by Victor Ambros [3], miRNAs are shown to be
important negative feedback regulators of many biologi-
cal processes such as development, differentiation, and
proliferation in vertebrates and plants. Aberrant expres-
sion of miRNAs in human cancer was first reported in
2002 for leukemia [4].
Since then multiple studies have found aberrant expres-
sion profiles of miRNAome in all major human cancers
(reviewed in [5]). While several target genes were experi-
mentally identified for some miRNAs in various tumors
[6], the global pattern of cellular functions and pathways
that are affected by miRNAs in cancer remains elusive.
In our recent studies we analyzed expression profiles of
more than 200 miRNAs in human cancer cells lines [7]
and samples of pancreatic tumors [8]. Using high-
throughput real-time PCR we found over one-hundred
miRNAs to be differentially expressed in pancreatic cancer
in comparison to normal pancreatic tissue. A cluster of
forty-seven most significantly over-expressed miRNAs
from this study was included in the current analysis along
with 4 other datasets published by others (breast, colon
and lung cancers [9], and lymphomas [10,11]).
miRNA expression signatures are shown to be specific and
allow classification of tumor type as well as different
stages in tumor progression and in some cases predict out-
come of a disease [12]. A number of studies have shown
that expression of some of the proteins affected in cancer
was negatively correlated with the expression of specific
miRNAs. Based on these findings, several groups have
hypothesized that miRNAs may play important role in
tumorigenesis and tumor progression and could function
as oncogenes or tumor suppressor genes [4,9]. However,
such global interpretation of miRNA expression profiling
data is impaired by the lack of high throughput target val-
idation methods and mostly relies upon computational
analysis of potential mRNA targets.
Computational algorithms have played a central role in
discovery of the majority of miRNAs known to date, as
well as in prediction of their targets (reviewed in [13-15]).
However, virtually all existing programs generate rela-
tively high levels of false positive predictions (up to a
twenty percent). Experimental evidence also suggests that
these programs generate some false negative predictions.
While bioinformatics methods continue to improve spe-
cificity and sensitivity of target predictions, the unresolved
challenge still remains to utilize even the most accurate
predictions for biologically meaningful interpretation of
miRNA profiling data. This problem is due to the fact that
the majority of known miRNAs are predicted to target a
very large number of transcripts. Each miRNA might have
up to several hundred targets. In addition, many tran-
scripts from protein-coding genes are targeted by more
than one miRNA and some transcripts might have over a
hundred target sites for different miRNAs. It has been esti-
mated that nearly 50% of all human gene transcripts are
regulated by relatively small number of 474 miRNAs that
are known to date with average of ~200 targets per miRNA
[13,14].
This conundrum of target multiplicity has become espe-
cially evident with the discovery of a large number of dif-
ferentially expressed miRNAs in many human cancers
[4,9]. A significant number of miRNAs in a range from ten
to one-hundred were found to be aberrantly expressed in
breast cancer, colon cancer, lung cancer, and other major
cancers with a predicted total number of targets ranging
from several hundred to as many as several thousand. This
again presents a problem for global analysis and the bio-
logical interpretation of the regulatory impact of miRNAs
in cancer cells. There is a clear need for data reduction
methods which would allow reducing the list of targets
and determining cellular processes that are most signifi-
cantly affected by miRNAs in cancer.
The Gene Ontology (GO) enrichment analysis is one of
the data reduction techniques that could be used to reduce
the number of targets of a large group of co-expressed
miRNAs and to find biological functions potentially
affected by multiple miRNAs.
The concept of combinatorial target regulation by miR-
NAs has been discussed in the literature [2,13,14] and was
incorporated into several current prediction algorithms
such as PicTar [13,14] and miRgate (Actigenics/Cepheid)
[16,17]. It is based on experimental evidence that some
co-expressed miRNAs may all target the same genes or
genes from the same functional categories. Several studies
have reported results of computational analysis of func-
tional annotation of genes targeted by single miRNAs
[18], all known miRNAs [19,20], or small groups of miR-
NAs that were selected based on high similarity of "seed"
sequences in the 5' region and/or large overlap of pre-
dicted target sets [21]. However, in case of experimentally
obtained miRNA profiling data these approaches are not
very practical when the task is to determine common bio-
logical functions and regulatory pathways that are tar-
geted by experimentally detected groups of co-expressed
miRNAs. Specifically in cancer such groups of miRNAs areBMC Bioinformatics 2007, 8(Suppl 7):S16 http://www.biomedcentral.com/1471-2105/8/S7/S16
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often found to have fewer common targeted genes and
not to share similar "seed" sequences.
In this study we address this problem of biological inter-
pretation of miRNA profiling data using systems biology
analysis of major biological proccesses, disease categories
and signalling pathways that are targeted collectively by
co-expressed miRNAs in cancer cells. We assumed that fil-
tering GO categories on the total number of hits by miR-
NAs targeting the same category would reduce the number
of false positive target predictions and at the same time
would allow narrowing down the large target lists and
determining those biological functions and pathways that
are most likely to be affected by co-expressed miRNAs.
Results
Data sets
Five groups of co-expressed miRNAs were selected from
the literature for this study: 3 groups that were reported by
Calin et al. [9] as being overexpressed in breast cancer (14
miRNAs), colon cancer (20 miRNAs) and lung cancer (33
miRNAs). We have also included a set of miRNAs that we
found to be significantly overexpressed in pancreatic can-
cer (47 miRNAs) [8]. An additional group of seven miR-
NAs was reported as being overexpressed in lymphomas
[10]. This group of miRNAs is encoded by a single gene
(cistron miR-17-92) and expressed as a single primary
transcript. Overexpression of cistron miR-17-92 was
found in B-lymphomas [10] and also was shown to have
strong correlation with T-lymphoma development in an
animal model [11]. These datasets were selected to repre-
sent the whole spectrum of group sizes of co-expressed
miRNAs that are observed in cancers: from a small set of
several co-expressed miRNAs (7 miRNAs, cistron miR-17-
92) to a large set (47 miRNAs, pancreatic cancer) to avoid
possible bias of sample size.
Combinatorial analysis of miRNA targets
Computational analysis of predicted targets for clusters of
overexpressed miRNAs was performed using novel combi-
natorial target prediction algorithms (miRgate 2.1 suite,
Actigenics/Cepheid [16,17]). Similar to other known
algorithms, a list of potential target sites (conserved
between human and mouse) on 3'-UTRs of human gene-
coding transcripts was determined based on a search for
complimentary binding sites for the sequence of "seed"
regions of 5'ends of mature miRNA positioned at 2–8
nucleotide region. These target lists were then analyzed by
several statistical methods. A flow diagram of data analy-
sis is shown on Figure 1.
Gene Ontology enrichment analysis
As a first step, the Gene Ontology (GO) [22] enrichment
analysis [23] of biological processes targeted by each of
five groups of miRNAs was performed using the miRgate
GO profiling algorithm that is specifically designed to
take in account information about the number of miRNAs
that are targeting the same genes and GO categories i.e.
number of miRNA hits per GO category (miRgate 2.1 suite
[16,17]). The GO categories were determined for all pre-
dicted targets of miRNAs from each of the five groups.
This set of GO categories was then filtered based on signif-
Flow Diagram of Data Analysis Figure 1
Flow Diagram of Data Analysis.
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icance of overrepresentation using a selected threshold for
p-values of hypergeometric distribution (p ≤ 0.05) [17].
An additional filter could then be applied to select only
those overrepresented GO categories which are targeted
by at least several miRNAs. For our study we have gener-
ated lists of all overrepresented GO categories for each
data set of over-expressed miRNAs from five types of can-
cer. The number of miRNAs targeting the same GO cate-
gory was included in the analysis and was used as the
parameter (Nm) under investigation.
Unsupervised hierarchical clustering of GO categories
The resulting matrices of enriched GO categories that were
affected by groups of co-expressed miRNA were further
analyzed by unsupervised hierarchical clustering using
information about the number of miRNAs targeted each
category to find similarities and differences in patterns of
affected biological functions for five types of cancer (Fig.
2). Using uncentered Pearson correlation as a distance the
clusters of GO categories that were specific for each cancer
were identified with a surprisingly low level of overlap.
Subsets of GO categories were generated by trimming the
original matrix on the minimal number of miRNAs target-
ing the same category (Nm ≥ threshold) and subjected to
hierarchical clustering to find categories targeted by the
number of miRNAs above the threshold. Resulting clus-
ters were compared among data sets from different can-
cers to determine how this trimming affects the clustering
results. We observed that trimming on Nm  actually
improved the separation of clusters of GO categories that
are specific for each cancer.
As an example a heat map with clustering results for Nm ≥
6 (i.e. at least 6 miRNAs targeting each GO category) is
included on Figure 3. A more detailed view of the same
clusters is presented as a bar graph (Figure 4). Each bar
represents a single GO category for each of five types of
cancer and showing the number of miRNAs that target the
same category. These clusters of GO Biological Processes
contain many categories known to be affected in cancer
such as general categories of proliferation, regulation of
cell cycle, and transcription, as well as more specific cate-
gories such as ras-oncogene signaling pathway, chromo-
some segregation, and others.
Systems Biology Analysis of predicted miRNA targets
For each set of co-expressed miRNAs we have generated 3
sets of predicted gene targets using GO ontology enrich-
ment analysis as a statistical filter:
1. Targets that belong to GO categories targeted by at least
one of the co-expressed miRNAs;
Heatmap of unsupervised hierarchical clustering of all Gene  Ontology (GO) categories obtained by enrichment analysis  for 5 datasets of miRNAs Figure 2
Heatmap of unsupervised hierarchical clustering of 
all Gene Ontology (GO) categories obtained by 
enrichment analysis for 5 datasets of miRNAs. Color 
gradient represents number of miRNAs targeting each cate-
gory.
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Heatmap of unsupervised hierarchical clustering of a subset of GO categories that are targeted by al least 6 miRNAs each Figure 3
Heatmap of unsupervised hierarchical clustering of a subset of GO categories that are targeted by al least 6 miRNAs each.
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2. Targets that belong to GO categories targeted by at least
50% of the co-expressed miRNAs;
3. Targets that belong to GO categories targeted by 100%
of the co-expressed miRNAs.
We started with raw lists of all targets predicted for each of
the miRNAs in a range from 2175 genes (cistron mir-17-
92) to 5356 genes (pancreatic cancer). Filtering raw sets of
predicted targets by miRgate GO enrichment analysis
algorithm provided significant reduction of target lists in
a range from 2.5 fold to over 4 fold (Table 1).
Three sets of genes were generated for each of 5 groups of
miRNAs and were then analyzed by Ingenuity Pathway
Analysis tools to determine major biological functions,
disease categories, toxicological and pathological catego-
ries, canonical signaling pathways, and drugs associated
with each data set.
To select most important functional categories and path-
ways for analysis and to understand relevance of affected
categories to the specific cancer, we generated reference
sets of genes for each of five cancers by keyword search of
the Ingenuity Knowledge Base. This search provided us
with very conservative lists of genes that were reported to
be affected in a specific cancer by multiple research groups
and were then manually curated by a group of expert biol-
ogists. These 5 reference sets of genes known to be affected
in lymphoma, breast cancer, colon cancer, lung cancer,
and pancreatic cancer were used in the Ingenuity Pathway
Analysis system to generate sets of biological functions,
disease categories, and pathways known to be most
affected in each of these cancers.
Bar graph of the same clusters of GO categories for 5 types of cancer that are presented on the Figure 3 Figure 4
Bar graph of the same clusters of GO categories for 5 types of cancer that are presented on the Figure 3.
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Comparative analysis of biological functions and disease 
categories
To evaluate the specific functional categories of genes
from broad GO categories that are targeted by miRNAs,
we performed more detailed analysis using IPA 5.0 (Inge-
nuity Systems, Redwood, CA). We compared gene sets
determined by GO enrichment algorithm against groups
of genes known to be affected in specific cancer to deter-
mine which top ranked categories would be statistically
enriched with miRNA targets. The results indicate that
many top ranked biological functions and disease catego-
ries as well as toxicological categories that were tissue spe-
cific for each specific cancer were also statistically
significantly overrepresented in our target lists. Top bio-
logical functions and disease related categories were com-
pared among 5 groups of data using gene lists generated
by trimming miRNA collectively targeted genes at the 50%
level (Fig. 5). The top ranked disease category for all 5
datasets was Cancer (Fig. 5B) with highly significant
enrichment (p ~ 10-10 ÷ 10-20). Within this top category we
identified a large number of genes known as tissue specific
biomarkers of each of 5 cancers. For example a list of
miRNA targets for colon cancer included APC gene (ade-
nomatosis polyposis coli) (Table 2) among other well
known oncogenes. For pancreatic cancer a list of miRNA
targets included both kras and p53 genes (Table 3) that
are well known biomarkers of pancreatic tumors [24].
Importantly, several Ras oncogenes were experimentally
validated as targets of multiple miRNAs from let-7 family
[25]. Overall, in our analysis we identified 25 known can-
cer related genes that have been already experimentally
validated as targets of miRNAs.
Other top ranked categories included tissue specific dis-
eases such as gastrointestinal systems diseases for colon
cancer; reproductive systems diseases for breast cancer etc.
(Fig. 5B).
The detailed information and statistics of IPA enrichment
analysis for all datasets are available in Additional Files
(Additional Files 1, 2, and 3). For example, the top 5 over-
represented functional categories for colon cancer
included cell death, cell growth and proliferation, cell
cycle, cell movement, and DNA replication and repair
(Additional File 1) and we found all of these categories to
be significantly overrepresented in our sets of predicted
miRNA targets. Similar results were obtained for pancre-
atic cancer (Additional File 2).
Comparative analysis of toxicology categories
Using IPA 5.0 we have also analyzed top ranked toxicol-
ogy related gene lists for each of five reference gene lists
and compared them with toxicology categories found in
our miRNA target lists (Additional File 4).
We found that 8 top ranked toxicology gene lists for each
cancer were statistically significantly overrepresented
among miRNA targets (Additional File 4). We found it
particularly interesting that several categories related to
oxidative stress and hypoxia were among top ranked over-
represented categories for miRNA targeted genes (Addi-
tional File 4). These findings are in agreements with recent
experimental data reporting over expression of multiple
miRNAs in response to oxidative stress or hypoxia [26]
and showing a functional link between hypoxia, a well-
known tumor microenvironment factor, and microRNA
expression.
Comparative pathway analysis
To further evaluate the specific functions of genes from
the broad GO categories that are targeted by miRNAs, we
performed additional, more detailed pathway analysis
(IPA 5.0, Ingenuity Systems). We compared gene sets
determined by GO enrichment algorithm against known
signaling pathways to determine which pathways would
be statistically enriched with miRNA targets. We were also
interested in determining which pathways were affected
the most by multiple miRNAs from the same co-expressed
group in each specific cancer.
To select pathways for analysis and to understand rele-
vance of affected pathways to the specific cancer, we used
Table 1: Number of predicted targets for 5 datasets
miRNA Data Set Number of co-
expressed miRNAs
Total Number of
Targets
Total number of
targets from
enrichment
analysis (GO BP), p
< 0.05
Number of targets
from GO BP
categories targeted
by >50% of miRNAs
Number of targets
from GO BP
categories targeted
by 100% of miRNAs
Lymphoma (cistron 
miR-17-92 only)
7 2175 962 918 851
Breast Cancer 14 3462 805 720 546
Colon Cancer 20 3439 828 711 578
Lung Cancer 33 4942 700 560 192
Pancreatic Cancer 47 5356 996 841 702BMC Bioinformatics 2007, 8(Suppl 7):S16 http://www.biomedcentral.com/1471-2105/8/S7/S16
Page 8 of 17
(page number not for citation purposes)
the same reference sets of genes for each of five cancers
that were obtained by keyword search of the Ingenuity
Knowledge Base. These 5 reference sets of genes known to
be affected in lymphomas, breast cancer, colon cancer,
lung cancer, and pancreatic cancer were used in the Inge-
nuity Pathway Analysis system to analyze sets of pathways
known to be affected in each of these cancers.
For each of the five datasets we performed analysis of all
canonical signaling pathways known to be affected by
each cancer to reveal pathways that are targeted by miR-
NAs from our datasets for each particular cancer. We used
Fisher's exact test to select pathways that were statistically
significantly enriched with miRNA targets (p ≤ 0.05).
The total number of targeted genes in each pathway was
compared with the number of reference genes from the
same pathway that are known to be affected by cancer. For
each type of cancer a reference set of genes was compared
with three target sets: a complete list of genes from
enriched GO categories and two sets trimmed by exclud-
ing genes from those GO categories that are targeted by
less than 50 percent or less than 100 percent of miRNAs
in a group.
For example, Figure 6 demonstrates the results of compar-
ison of top 12 pathways known to be affected by colon
cancer and targeted by miRNAs that are over-expressed in
colon cancer. Bar color represents 4 data sets: dark blue –
reference gene list for colon cancer generated by Ingenuity
Knowledgebase; medium blue, light blue and black – 3
gene lists that were obtained from GO enrichment analy-
sis; a complete list (all targets) and two sets trimmed by
excluding genes from GO categories targeted by less than
50% or less than 100% of miRNAs in the group. The same
type of comparison of top 12 pathways for pancreatic can-
cer is shown on Figure 7.
Results of the pathway analysis were similar for all data-
sets. We found that a large fraction of pathways known to
Table 2: List of predicted targets that are known genes affected in Colon Cancer
Name Description Location Type Drugs
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, 
gamma)
Cytoplasm kinase enzastaurin
APC adenomatosis polyposis coli Nucleus enzyme
BAX BCL2-associated X protein Cytoplasm other
BCL2L11 BCL2-like 11 (apoptosis facilitator) Cytoplasm other
BIRC5 baculoviral IAP repeat-containing 5 (survivin) Cytoplasm other
BRCA1 breast cancer 1, early onset Nucleus transcription regulator
CCND1 cyclin D1 Nucleus other
DIABLO diablo homolog (Drosophila) Cytoplasm other
EP300 E1A binding protein p300 Nucleus transcription regulator
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) Plasma Membrane kinase
FASLG Fas ligand (TNF superfamily, member 6) Extracellular Space cytokine
FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/
vascular permeability factor receptor)
Plasma Membrane kinase sunitinib, axitinib
FST follistatin Extracellular Space other
GSK3A glycogen synthase kinase 3 alpha Nucleus kinase
ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen 
CD29 includes MDF2, MSK12)
Plasma Membrane transmembrane receptor
MAP2K1 mitogen-activated protein kinase kinase 1 Cytoplasm kinase PD 0325901
MAPK9 mitogen-activated protein kinase 9 Cytoplasm kinase
MAPK14 mitogen-activated protein kinase 14 Cytoplasm kinase SCIO-469
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive Nucleus transcription regulator
NUAK1 NUAK family, SNF1-like kinase, 1 Unknown kinase
PARP1 poly (ADP-ribose) polymerase family, member 1 Nucleus enzyme INO-1001
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) Nucleus other
PLK1 polo-like kinase 1 (Drosophila) Nucleus kinase
PPP2R1B protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), 
beta isoform
Unknown phosphatase
PRKCA protein kinase C, alpha Cytoplasm kinase safingol
PRKG1 protein kinase, cGMP-dependent, type I Cytoplasm kinase
SRC v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(avian)
Cytoplasm kinase dasatinib
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) Plasma Membrane kinase
YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 Cytoplasm kinase dasatinibBMC Bioinformatics 2007, 8(Suppl 7):S16 http://www.biomedcentral.com/1471-2105/8/S7/S16
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be affected in a particular cancer was also collectively tar-
geted by co-expressed miRNAs that were experimentally
detected in that cancer. However the sets of most affected
pathways were specific for each type of cancer (Additional
File 5).
The detailed inspection of overlay diagrams revealed an
interesting pattern of genes targeted by miRNAs. In the
majority of inspected pathways the miRNA targets were
often different from genes known to be affected by cancer
and were found among genes that are directly down-
stream and/or upstream of the cancer related genes in the
same branches of signaling cascades (Figures 8, 9, 10, 11,
Additional file 6).
All overlay diagrams show target genes (highlighted in
gray color) corresponding to a set of target genes from sta-
tistically enriched GO categories targeted by at least 50%
of miRNAs in a group. This type of analysis was performed
on all five datasets.
Two examples are shown for colon cancer (Figures 8, 9)
and two – for pancreatic cancer (Figures 10, 11), with
additional data presented for lymphoma in Additional
File 6.
In many pathways we found that miRNAs target multiple
kinases that are important mediators of signal transduc-
tion pathways and are often targeted by anticancer drugs
known as kinase inhibitors (specific examples are pro-
vided in the next section). Since all miRNAs in this study
were over-expressed in cancer, their overall effect would
be to down-regulate many or, sometimes, all of the abnor-
mally activated alternative signal transduction cascades in
most of the pathways known to be affected by a particular
cancer. Such effect would be comparable with the effect of
several kinase inhibitor drugs combined.
Anti-cancer drugs and microRNA targets
Using IPA knowledge base (Ingenuity Systems, Redwood,
CA) we have analyzed known anticancer drugs and found
that several drugs are targeting the same cancer related
genes as the miRNAs (Tables 2, 3 and Additional Files 7,
8) including several experimentally validated microRNA
targets.
One of the most common groups of drugs sharing the
same targets with miRNAs was a relatively new class of
kinase inhibitors that are designed to inhibit abnormally
activated kinases in signal transduction pathways in can-
cer cells. Analysis of pathways diagrams has shown that
many of these kinase inhibitors target the same kinases as
do miRNAs.
For example, we found that multiple genes from p38 sig-
naling pathway are affected in colon cancer and that
kinase inhibitor drug SCIO targets all 4 izoforms of the
p38 MAP kinase super-family effectively down regulating
Table 3: List of predicted targets that are known genes affected in Pancreatic Cancer
Name Description Location Type Drugs
AKT1 v-akt murine thymoma viral oncogene 
homolog 1
Cytoplasm kinase enzastaurin
BCL2 B-cell CLL/lymphoma 2 Cytoplasm other oblimersen
CCKBR cholecystokinin B receptor Plasma Membrane G-protein coupled receptor CR 2945
CDK6 cyclin-dependent kinase 6 Nucleus kinase flavopiridol
CTSB cathepsin B Cytoplasm peptidase
CTSL2 cathepsin L2 Cytoplasm peptidase
E2F1 E2F transcription factor 1 Nucleus transcription regulator
FAS Fas (TNF receptor superfamily, member 6) Plasma Membrane transmembrane receptor
HGF hepatocyte growth factor (hepapoietin A; 
scatter factor)
Extracellular Space growth factor
HMGA1 high mobility group AT-hook 1 Nucleus transcription regulator
IL6 interleukin 6 (interferon, beta 2) Extracellular Space cytokine
KRAS v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog
Cytoplasm enzyme
PLAU plasminogen activator, urokinase Extracellular Space peptidase
RHOB ras homolog gene family, member B Cytoplasm enzyme
THOC1 THO complex 1 Nucleus other
TOP1 topoisomerase (DNA) I Nucleus enzyme elsamitrucin, T 0128, CT-2106, BN 
80927, tafluposide, TAS-103, 
irinotecan, topotecan, 9-amino-20-
camptothecin, rubitecan, gimatecan, 
karenitecin
TP53 tumor protein p53 (Li-Fraumeni syndrome) Nucleus transcription regulatorBMC Bioinformatics 2007, 8(Suppl 7):S16 http://www.biomedcentral.com/1471-2105/8/S7/S16
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all branches of this signal transduction pathway (Figure
9A). Interestingly, three of these genes are also predicted
targets of miRNAs that are co-expressed in colon cancer
(Figure 9B). The p38 MAP kinase pathway plays an impor-
tant function in the cellular response after infection by
pathogens or inflammatory stimulation and has been also
implicated in breast, colon and other types of cancer
[27,28].
We found similar examples of other pathways with kinase
genes that are targeted by both the anticancer drugs and
miRNAs.
We have also found other types of genes that are targeted
by anticancer drugs and miRNAs within the same path-
ways. For instance we found that apoptosis signaling
pathway has many genes affected in pancreatic cancer
including two critical regulators of apoptosis: Bcl-2 and
Caspase-3 (Figure 11A). Bcl-2 is targeted by recently devel-
oped drug oblimesen which is an antisense synthetic oli-
gonucleotyde-based anticancer (pro-apoptotic) drug
effectively silencing Bcl-2 transcripts (Figure 11A).
Capase-3 is targeted by IDN-6556, an anti-apoptotic drug
(caspase inhibitor) which is indicated for hepatitis C.
Both of these genes are also predicted targets of miRNAs
that are over-expressed in pancreatic cancer (Fig. 11B).
Bcl-2 encodes an integral mitochondrial outer membrane
protein that blocks the apoptotic death of some cells such
as lymphocytes. Constitutive expression of Bcl-2 is
thought to be the cause of some types of cancer [29].
Therefore down regulation of Bcl-2 by over expressed
miRNAs would have pro-apoptotic anticancer effect simi-
lar to the effect of oblimesen.
Importantly, Bcl-2 is one of the few microRNA targets that
were confirmed experimentally to be targeted collectively
by at least two miRNAs. It has been recently shown by
Cimmino et al. [29] that miR-15a and miR-16-1 expres-
sion is inversely correlated with Bcl-2 expression in CLL
and that both miRNAs negatively regulate Bcl-2. It has
also been shown that repression of Bcl-2 by these miRNAs
induces apoptosis in leukemia cell lines. The authors of
this study have proposed that miR-15 and miR-16 are nat-
ural antisense Bcl-2 regulators that could be used for can-
cer therapy of some tumors.
Comparison of top 10 biological function categories and disease categories enriched with miRNA target genes from 5 datasets  of over expressed miRNAs Figure 5
Comparison of top 10 biological function categories and disease categories enriched with miRNA target genes from 5 datasets 
of over expressed miRNAs.
B.  Disease Categories
A.  Biological FunctionsBMC Bioinformatics 2007, 8(Suppl 7):S16 http://www.biomedcentral.com/1471-2105/8/S7/S16
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Paradoxically, down regulation of caspase-3 by miRNAs
should have anti-apoptotic effect similar to the effect of
IDN-6556 and would be beneficial for cancer cell survival.
This counterintuitive mode of miRNA regulation has been
recently discussed in the literature in a context of relevant
experimental observations showing that miR-34a has
tumor suppressor activity when ectopically expressed in
NB cell lines through induction of caspase 3/7 apoptotic
pathway [30]. miR-34a may have a pro-apoptotic effect, in
part, through targeting the E2F3 transcription factor.
Recently, it has been shown that miR-17-5p and miR-20a
also act as tumor suppressors by targeting and reducing
E2F1 levels [31]. Similar to miR-34a, the chromosome
region with the miR-17 cluster is deleted in some human
tumors. This same region, however, is amplified in diffuse
large B-cell lymphoma samples [29]. Thus miRNAs may
have a tumor suppressor or oncogenic effect depending
upon the cell type in which they are expressed. It is also
important to keep in mind that when multiple miRNAs
are co-expressed within the same tumor cells a systemic
regulatory impact should be considered in a context of
many regulatory targets that are affected simultaneously.
In case of pancreatic cancer we have found that E2F1 is a
predicted microRNA target as well as caspase3. E2F1 has
been also validated experimentally as a target of multiple
miRNAs [30]. In this regard, it is interesting to note that
similar complex regulatory responses were previously
reported for the members of E2F family of transcription
factors that can also have cell proliferative or pro-apop-
totic effects in different cellular and regulatory contexts
[[32], 33].
Discussion
In this study we have addressed the problem of identify-
ing major biological processes and signaling pathways
that are targeted collectively by co-expressed miRNAs in
Comparison of 12 pathways known to be affected in colon cancer and targeted by miRNAs that are over-expressed in colon  cancer Figure 6
Comparison of 12 pathways known to be affected in colon cancer and targeted by miRNAs that are over-
expressed in colon cancer. Color of the bars represents 4 data sets. Detailed description could be found in the Results sec-
tion. A. Ratio of affected genes to total number of genes in the pathway. Reference gene set and three target sets are included: 
a complete list (all targets) and two sets trimmed by excluding genes from GO categories targeted by less than 50% or less 
than 100% of miRNAs in the group. B. Significance of enrichment. Threshold p < 0.05 is shown as yellow line. Bars that are 
above the line indicate significant enrichment of a pathway.
B.
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cancer cells. Recently, multiple studies have reported aber-
rant expression profiles of miRNAome in human cancers.
Several target genes were experimentally identified for
some miRNAs in various tumors; however the global pat-
tern of cellular functions and pathways affected by miR-
NAs in cancer remains elusive. We proposed a two step
data reduction procedure and have tested it on experi-
mentally obtained data sets of aberrantly expressed miR-
NAs in five human cancers.
First, we performed a statistical enrichment analysis of GO
categories to find categories that are enriched with targets
of co-expressed miRNAs. The miRgate GO profiling algo-
rithm is specifically designed to take in account informa-
tion about the number of miRNAs that are targeting the
same genes and information about the number of miR-
NAs hits per GO category [17]. It allowed us to reduce a
very large raw list of predicted target genes to a smaller set
of target genes from significantly enriched GO categories.
Second, we have tested the idea that additional trimming
of the over-represented GO categories on the total
number of hits by multiple miRNAs would allow determi-
nation of those biological functions that were affected the
most by miRNAs and that were more specific for each can-
cer. It has been shown in simulation studies [13] that the
level of random noise in miRNA target predictions
declined sharply even with trimming by condition of at
least 3 miRNAs targeting each of the same genes. Even
though we have already filtered the target list on signifi-
cance of GO enrichment, we assume that using additional
criteria of multiple miRNAs targeting the same categories
would reduce the random predictions noise even further.
Comparison of 12 pathways known to be affected in Pancreatic Cancer and targeted by miRNAs that are over-expressed in  Pancreatic Cancer Figure 7
Comparison of 12 pathways known to be affected in Pancreatic Cancer and targeted by miRNAs that are over-
expressed in Pancreatic Cancer. Color of the bars represents 4 data sets. Detailed description could be found in the 
Results section. A. Ratio of affected genes to total number of genes in the pathway. Reference gene set and three target sets 
are included: a complete list (all targets) and two sets trimmed by excluding genes from GO categories targeted by less than 
50% or less than 100% of miRNAs in the group. B. Significance of enrichment. Threshold p < 0.05 is shown as yellow line. Bars 
that are above the line indicate significant enrichment of a pathway.
B.
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We have tested this assumption by performing unsuper-
vised clustering analysis of GO categories using the
number of miRNAs that target each category to calculate
correlation-based distance and to find groups of catego-
ries that were most specifically targeted for each cancer
and to determine how trimming on the number of target-
ing miRNAs would affect these clusters. Our results show
that trimming actually improved the separation of clus-
ters.
Diagram of PTEN Signaling Pathway Figure 8
Diagram of PTEN Signaling Pathway. A. Genes known to be affected in Colon Cancer are shown in gray. B. Genes from 
significantly enriched GO categories that are targeted by at least 50% of over-expressed miRNAs from Colon Cancer dataset 
are shown in gray
A. B.
Diagram of p38 signaling pathway Figure 9
Diagram of p38 signaling pathway. A. Genes known to be affected in Colon Cancer are shown in gray. B. Genes from sig-
nificantly enriched GO categories that are targeted by at least 50% of over-expressed miRNAs from Colon Cancer dataset are 
shown in gray. Drug that are known to target this signaling pathway are outlined in dark blue. Drug targets are outlined in light 
blue.
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We have further investigated the effect of trimming in
pathway analysis where only significantly overrepresented
canonical pathways were selected and compared against
reference gene sets known to be affected in particular can-
cer types. We found that for the majority of pathways the
trimming on the number of miRNAs targeting the same
GO category produced little or no change in the number
of affected genes and at times even provided additional
improvement on the significance of enrichment (Figs. 6B,
7B), most probably by eliminating unrelated genes that
were diluting the target gene set.
Clustering analysis of enriched GO categories and path-
ways analysis of major signaling pathways have both
shown that using additional criteria of multiple miRNA
targeting of the same category allows narrowing down the
sets of predicted targets without losing the specificity of
cancer related gene lists.
Using a combinatorial target prediction algorithm we
have found GO categories as well as biological functions,
disease categories, toxicological categories, and regulatory
pathways that are: targeted by multiple miRNAs; statisti-
cally significantly enriched with target genes; and known
Diagram of Integrin Signaling Pathway Figure 10
Diagram of Integrin Signaling Pathway. A. Genes known to be affected in Pancreatic Cancer are shown in gray. B. Genes 
from significantly enriched GO categories that are targeted by at least 50% of over-expressed miRNAs from Pancreatic Cancer 
dataset are shown in gray
B.
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to be affected in specific cancers. Importantly, several well
known cancer related genes such as ras, Bcl-2 and E2F1
that we identified in our analysis have been already vali-
dated in wet lab experiments and were reported by others
as targets of multiple miRNAs [25,29,31]. Overall, in our
analysis we identified 25 known cancer related genes that
have been already experimentally validated as targets of
miRNAs.
Our pathway analysis suggests that co-expressed miRNAs
seem to collectively targeting a broad range of down-
stream signaling cascades and down regulating expression
of genes in abnormally activated pathways. Such compu-
tationally inspired hypothesis could be tested experimen-
tally by comparing microRNA expression data with
mRNA expression data and protein expression data
obtained from the same samples of the tumor tissue.
Conclusion
Our global analysis of predicted miRNA targets in 5
human cancers demonstrates that co-expressed miRNAs
might collectively provide systemic compensatory
response to the abnormal functional and phenotypic
changes in cancer cells by targeting a broad range of func-
tional categories and abnormally activated pathways
known to be affected in a particular cancer. Such systems
biology based approach could provide new avenues for
biological interpretation of miRNA profiling data as well
as generation of experimentally testable hypotheses
regarding collective regulatory functions of miRNA in can-
cer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YG designed and performed this study, YG and DB wrote
the manuscript. TS, MG and RP provided guidance with
biological interpretation, comments on the study and on
the manuscript. All authors read and approved the final
manuscript.
Additional material
Additional file 1
Supplemental Figure 2 – Top ranked biological functions and disease 
categories targeted by miRNAs and known to be affected in Colon 
Cancer. A. Top 5 Biological Functions. B. Top 5 Disease Categories
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S1.doc]
Diagram of Apoptosis Signaling Pathway Figure 11
Diagram of Apoptosis Signaling Pathway. A. Genes known to be affected in Pancreatic Cancer are shown in gray. B. 
Genes from significantly enriched GO categories that are targeted by at least 50% of over-expressed miRNAs from Pancreatic 
Cancer dataset are shown in gray. Drug that are known to target genes from this signaling pathway are outlined in dark blue. 
Drug targets are outlined in light blue.
A. B.BMC Bioinformatics 2007, 8(Suppl 7):S16 http://www.biomedcentral.com/1471-2105/8/S7/S16
Page 16 of 17
(page number not for citation purposes)
Acknowledgements
We would like to thank Olivier Delfour for technical assistance and on-line 
support in using miRgate software suite.
This article has been published as part of BMC Bioinformatics Volume 8 Sup-
plement 7, 2007: Proceedings of the Fourth Annual MCBIOS Conference. 
Computational Frontiers in Biomedicine. The full contents of the supple-
ment are available online at http://www.biomedcentral.com/1471-2105/
8?issue=S7.
References
1. Ambros V: The functions of animal miRNAs.  Nature 2004,
431:350-355.
2. Bartel DP: MiRNAs: genomics, biogenesis, mechanism, and
function.  Cell 2004, 116:281-297.
3. Lee RC, Rhonda L, Feinbaum RL, Ambros V: The C. elegans hete-
rochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14.  Cell 1993, 75:843-854.
4. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler
H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich
F, Croce CM: Frequent deletions and down-regulation of
micro-RNA genes miR15 and miR16 at 13q14 in chronic lym-
phocytic leukemia.  Proc Natl Acad Sci USA 2002, 99:15524-15529.
5. Calin GA, Croce CM: MiRNA signatures in human cancers.  Nat
Rev Cancer 2006, 6(11):857-66.
6. Adams BD, Furneaux H, White B: The micro-RNA miR-206 Tar-
gets the Human Estrogen Receptor-{alpha}, and Represses
ER {alpha} mRNA and Protein Expression in Breast Cancer
Cell Lines.  Mol Endocrinol  in press. 2007, Mar 13
7. Jiang J, Lee EJ, Gusev Y, Schmittgen TD: Real-time expression pro-
filing of miRNA precursors in human cancer cell lines.  Nucleic
Acids Res 2005, 33(17):5394-403.
8. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan
DL, Postier RG, Brackett DJ, Schmittgen TD: Expression profiling
identifies miRNA signature in pancreatic cancer.  Int J Cancer
2007, 120(5):1046-54.
9. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone
R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G,
Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A miRNA
expression signature of human solid tumors defines cancer
gene targets.  Proc Natl Acad Sci USA 2006, 103:2257-2261.
10. He1 L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Good-
son S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Scott M,
Hammond SM: A miRNA polycistron as a potential human
oncogene.  Nature 2005, 435:828-833.
11. Wang CL, Wang BB, Bartha G, Li L, Channa N, Klinger M, Killeen N,
Wabl M: Activation of an oncogenic miRNA cistron by provi-
rus integration.  Proc Natl Acad Sci USA 2006, 103:18680-18684.
12. Chen Y, Stallings RL: Differential patterns of miRNA expression
in neuroblastoma are correlated with prognosis, differentia-
tion, and apoptosis.  Cancer Res 2007, 67(3):976-83.
13. Chen K, Rajewsky N: Natural selection on human miRNA bind-
ing sites inferred from SNP data.  Nature Genetics 2006,
38:1452-1456.
14. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMe-
namin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combi-
natorial miRNA target predictions.  Nature Genetics 2005,
37:495-500.
15. John B, Sander C, Marks DS: Prediction of human miRNA tar-
gets.  Methods Mol Biol 2006, 342:101-13.
16. miRgate 2.1 suite, Actigenics/Cepheid   [http://www.actigen
ics.com]
17. Delfour O, Vilanova D, Atzorn V, Michot B: The passionate race
for miRNA detection and function deciphering.  In miRNA: Biol-
ogy, Function and Expression Edited by: Clarke NJ, Sanseau P. DNA Press;
2007:335-362. 
18. Wang X, Wang X: Systematic identification of microRNA func-
tions by combining target prediction and expression profil-
ing.  Nucleic Acids Research 2006, 34(5):1646-1652.
19. Cui Q, Yu Z, Purisima EO, Wang E: Principles of microRNA reg-
ulation of a human cellular signaling network.  Mol Syst Biol
2006, 2:46.
Additional file 2
Supplemental Figure 3 – Top ranked biological functions and disease 
categories targeted by miRNAs and known to be affected in Pancreatic 
Cancer. A. Top 5 Biological Functions. B. Top 5 Disease Categories
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S2.doc]
Additional file 3
Top 5 functions, disease categories and toxicology lists for 5 cancers.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S3.xls]
Additional file 4
Supplemental Figure 1 – Comparison of Toxicology categories and 
canonical pathways targeted by miRNA for 5 types of cancer. A. Toxi-
cology related gene lists from top ranked Toxicology categories. B. Top 
ranked Canonical Pathways
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S4.doc]
Additional file 5
Supplemental Figure 5 – Comparison of top ranked signaling path-
ways targeted by microRNAs in 5 types of cancer. A. Ratio of the 
number of genes targeted by miRNAs to the total number of genes in each 
pathway. B. Significance of overrepresentation of microRNA targets in 
each pathway
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S5.doc]
Additional file 6
Supplemental Figure 4 – TGF-b Signaling pathway. A. Genes known 
to be affected in Lymphoma (shown in gray) and known anticancer drugs. 
B. Targets of microRNA family miR-17-92 (shown in gray) and targets 
of known anticancer drugs. Drug that are known to target genes from this 
signaling pathway are outlined in dark blue. Drug targets are outlined in 
light blue.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S6.doc]
Additional file 7
Supplemental Table 1 – Number of predicted miRNA target genes known 
to be associated with specific or any cancer and targeted by anti-cancer 
drugs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S7.doc]
Additional file 8
Supplemental Tables: genes known to be affected in specific cancer and 
targeted by miRNAs (lymphoma, breast cancer, lung cancer).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-S7-S16-S8.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Bioinformatics 2007, 8(Suppl 7):S16 http://www.biomedcentral.com/1471-2105/8/S7/S16
Page 17 of 17
(page number not for citation purposes)
20. Gaidatzis D, van Nimwegen E, Hausser J, Zavolan M: Inference of
miRNA targets using evolutionary conservation and path-
way analysis.  BMC Bioinformatics 2007, 8:69.
21. Yoon S, De Micheli G: Prediction of regulatory modules com-
prising microRNAs and target genes.  Bioinformatics 2005,
21(Suppl 2):ii93-ii100.
22. Gene Ontology Consortium: The Gene Ontology (GO) project
in 2006.  Nucleic Acids Res 2006, 34(Database):D322-D326.
23. Beissbarth T, Speed TP: GOstat: find statistically overrepre-
sented Gene Ontologies within a group of genes.  Bioinformatics
2004, 20:1464-1465.
24. Dergham ST, Dugan MC, Kucway R, Du W, Kamarauskiene DS,
Vaitkevicius VK, Crissman JD, Sarkar FH: Prevalence and clinical
significance of combined K-ras mutation and p53 aberration
in pancreatic adenocarcinoma.  Int J Pancreatol 1997,
21(2):127-43.
25. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A,
Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by
the let-7 microRNA family.  Cell 2005, 120(5):635-47.
26. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-
Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan
M:  A microRNA signature of hypoxia.  Mol Cell Biol 2007,
27(5):1859-67.
27. Zarubin T, Han J: Activation and signaling of the p38 MAP
kinase pathway.  Cell Res 2005, 15:11-18.
28. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA: Breast
Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Hereg-
ulin-Induced Activation of ERK5 and p38 MAP Kinases in
Breast Cancer Cells.  Cancer Res 2007, 67(9):4199-209.
29. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M,
Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia
S, Liu CG, Kipps TJ, Negrini M, Croce CM: miR-15 and miR-16
induce apoptosis by targeting BCL2.  Proc Natl Acad Sci USA
2005, 102(39):13944-9.
30. Welch C, Chen Y, Stallings RL: MicroRNA-34a functions as a
potential tumor suppressor by inducing apoptosis in neurob-
lastoma cells.  Oncogene . advance online publication 12 February
2007; doi: 10.1038/sj.onc.1210293
31. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-
regulated microRNAs modulate E2F1 expression.  Nature
2005, 435:839-843.
32. Johnson DG, Degregori J: Putting the Oncogenic and Tumor
Suppressive Activities of E2F into Context.  Curr Mol Med 2006,
6:731-738.